Use of voriconazole in fungal keratitis.
Jones
Andrew
A
Muhtaseb
Mohammed
M
D000284:Administration, Oral; D000287:Administration, Topical; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D002701:Chloramphenicol / Q000627:therapeutic use; D003261:Contact Lenses / Q000382:microbiology; D003320:Corneal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D015821:Eye Infections, Fungal / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D014230:Triazoles / Q000627:therapeutic use*; D014792:Visual Acuity; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D002701:Chloramphenicol; D065819:Voriconazole